Sakitani Kosuke, Hirata Yoshihiro, Hikiba Yohko, Hayakawa Yoku, Ihara Sozaburo, Suzuki Hirobumi, Suzuki Nobumi, Serizawa Takako, Kinoshita Hiroto, Sakamoto Kei, Nakagawa Hayato, Tateishi Keisuke, Maeda Shin, Ikenoue Tsuneo, Kawazu Shoji, Koike Kazuhiko
The Institute for Adult Diseases, Asahi Life Foundation, 2-2-6 Bakuro-cho, Nihon-Bashi, Chuo-ku, Tokyo, 113-8655, Japan.
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
BMC Cancer. 2015 Oct 24;15:795. doi: 10.1186/s12885-015-1789-5.
Although some molecularly targeted drugs for colorectal cancer are used clinically and contribute to a better prognosis, the current median survival of advanced colorectal cancer patients is not sufficient. Autophagy, a basic cell survival mechanism mediated by recycling of cellular amino acids, plays an important role in cancer. Recently, autophagy has been highlighted as a promising new molecular target. The unfolded protein response (UPR) reportedly act in complementary fashion with autophagy in intestinal homeostasis. However, the roles of UPR in colon cancer under autophagic inhibition remain to be elucidated. We aim to clarify the inhibitory effect of autophagy on colon cancer.
We crossed K19 (CreERT) and Atg5 (flox/flox) mice to generate Atg5 (flox/flox)/K19 (CreERT) mice. Atg5 (flox/flox)/K19 (CreERT) mice were first treated with azoxymethane/dextran sodium sulfate and then injected with tamoxifen to inhibit autophagy in CK19-positive epithelial cells. To examine the anti-cancer mechanisms of autophagic inhibition, we used colon cancer cell lines harboring different p53 gene statuses, as well as small interfering RNAs (siRNAs) targeting Atg5 and immunoglobulin heavy-chain binding protein (BiP), a chaperone to aid folding of unfolded proteins.
Colon tumors in Atg5 (flox/flox)/K19 (CreERT) mice showed loss of autophagic activity and decreased tumor size (the total tumor diameter was 28.1 mm in the control and 20.7 mm in Atg5 (flox/flox)/K19 (CreERT) mice, p = 0.036). We found that p53 and UPR/endoplasmic reticulum (ER) stress-related proteins, such as cleaved caspase 3, and CAAT/enhancer-binding protein homologous protein, are up-regulated in colon tumors of Atg5 (flox/flox)/K19 (CreERT) mice. Although Atg5 and BiP silencing, respectively, increased apoptosis in p53 wild type cells, Atg5 silencing alone did not show the same effect on apoptosis in p53 mutant cells. However, co-transfection of Atg5 and BiP siRNAs led to increased apoptosis in p53 mutant cells.
Blocking autophagy has potential in the treatment of colon cancer by inducing apoptosis via p53 and ER stress, and suppressing the UPR pathway is a valid strategy to overcome resistance to autophagic inhibition.
尽管一些用于结直肠癌的分子靶向药物已应用于临床并有助于改善预后,但晚期结直肠癌患者目前的中位生存期仍不尽人意。自噬是一种由细胞氨基酸循环介导的基本细胞存活机制,在癌症中发挥重要作用。最近,自噬已成为一个有前景的新分子靶点。据报道,未折叠蛋白反应(UPR)在肠道稳态中与自噬以互补方式发挥作用。然而,在自噬抑制情况下UPR在结肠癌中的作用仍有待阐明。我们旨在阐明自噬对结肠癌的抑制作用。
我们将K19(CreERT)和Atg5(flox/flox)小鼠杂交,以生成Atg5(flox/flox)/K19(CreERT)小鼠。Atg5(flox/flox)/K19(CreERT)小鼠首先用氧化偶氮甲烷/葡聚糖硫酸钠处理,然后注射他莫昔芬以抑制CK19阳性上皮细胞中的自噬。为了研究自噬抑制的抗癌机制,我们使用了具有不同p53基因状态的结肠癌细胞系,以及靶向Atg5和免疫球蛋白重链结合蛋白(BiP)的小干扰RNA(siRNA),BiP是一种帮助未折叠蛋白折叠的伴侣蛋白。
Atg5(flox/flox)/K19(CreERT)小鼠的结肠肿瘤显示出自噬活性丧失且肿瘤大小减小(对照组的总肿瘤直径为28.1mm,Atg5(flox/flox)/K19(CreERT)小鼠为20.7mm,p = 0.036)。我们发现,在Atg5(flox/flox)/K19(CreERT)小鼠的结肠肿瘤中,p53和UPR/内质网(ER)应激相关蛋白,如裂解的半胱天冬酶3和CAAT/增强子结合蛋白同源蛋白,上调。虽然分别沉默Atg5和BiP会增加p53野生型细胞中的凋亡,但单独沉默Atg5对p53突变型细胞中的凋亡没有相同作用。然而,共转染Atg5和BiP siRNA会导致p53突变型细胞中的凋亡增加。
阻断自噬通过p53和内质网应激诱导凋亡在结肠癌治疗中具有潜力,抑制UPR途径是克服对自噬抑制耐药的有效策略。